0
0
December 4, 2025
Washington, D.C. – The U.S. Food and Drug Administration (FDA) has approved Armlupeg (pegfilgrastim-unne), a new biosimilar to Neulasta (pegfilgrastim), aimed at preventing life-threatening infections in cancer patients undergoing chemotherapy. The approval, granted to Lupin Limited earlier this week, marks a significant addition to the growing portfolio of affordable biologic treatments available to U.S. patients.
Armlupeg is indicated to decrease the incidence of infection, specifically febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. It is also approved to increase survival in patients acutely exposed to myelosuppressive doses of radiation.
Expanding Access to Critical Care
Febrile neutropenia is a serious side effect of chemotherapy where the patient’s white blood cell count drops dangerously low, leaving them vulnerable to severe infections. Drugs like Neulasta and its biosimilars work by stimulating the bone marrow to produce more neutrophils, a type of white blood cell that fights infection.
The approval of Armlupeg offers healthcare providers and patients another therapeutic option in a market designed to lower healthcare costs through competition. Biosimilars are biologic products that are highly similar to and have no clinically meaningful differences from an existing FDA-approved reference product.
“We are proud to achieve the FDA approval for our first biosimilar, pegfilgrastim,” said Vinita Gupta, CEO of Lupin Limited, in a press statement. “This step marks a pivotal step in Lupin’s ongoing commitment to providing more affordable, accessible medicines to U.S. patients.”
Clinical Significance and Safety
The FDA’s decision was based on a comprehensive review of evidence demonstrating that Armlupeg is biosimilar to Neulasta. This included structural and functional characterization, animal data, and human pharmacokinetic and pharmacodynamic data.
“For oncologists, having multiple biosimilar options is crucial,” explains Dr. Sarah Miller, a hematologist-oncologist at City Hope Medical Center (who was not involved in the Lupin application). “It helps mitigate drug shortages and, importantly, drives down costs for both health systems and patients, making essential supportive care more accessible.”
The clinical data supporting Armlupeg confirms that it matches the safety and efficacy profile of the reference product. Common side effects associated with pegfilgrastim products include bone pain and pain in the extremities. Serious but rare adverse reactions can include splenic rupture, acute respiratory distress syndrome (ARDS), and serious allergic reactions.
Market Context and Public Health Impact
Armlupeg enters a competitive landscape already populated by other Neulasta biosimilars such as Fulphila, Udenyca, and Ziextenzo. However, the demand for these agents remains high given the prevalence of chemotherapy regimens that suppress the immune system.
According to IQVIA data, the U.S. market for pegfilgrastim was estimated at approximately $1.29 billion annually as of September 2025. The introduction of Armlupeg is expected to contribute to further cost reductions in oncology care, a sector where financial toxicity is a major concern for patients.
Nilesh Gupta, Managing Director at Lupin, highlighted the manufacturing quality behind the new drug: “Our integrated biologic capabilities… coupled with our state-of-the-art biologic facility that has now been approved by every major regulatory body, ensures that we deliver biosimilars that meet the highest global quality standards.”
Implications for Patients
For patients currently undergoing or scheduled for chemotherapy, this approval does not require a change in their treatment plan unless advised by their physician. However, it provides hospitals and insurance formularies with more leverage to negotiate prices, potentially lowering co-pays and out-of-pocket expenses for this class of drugs.
“Patients should view this as a positive development,” Dr. Miller added. “It reinforces that the biosimilar pathway is working to bring high-quality, effective alternatives to the market.”
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
-
Lupin Limited. (2025, December 1). Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg™ (Pegfilgrastim-unne) [Press release].
